Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Alho, D. Sinclair, E. Vuori, A. Holopainen (2007)
Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.Drug and alcohol dependence, 88 1
(2009)
Results from the 2008 National Survey on Drug Use and Health: National Findings
W Guy
ECDEU Assessment Manual for Psychopharmacology.
A. Winstock, Toby Lea, J. Sheridan (2008)
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.The International journal on drug policy, 19 6
(1999)
Individual Drug Counseling
R. Bruce, Sumathi Govindasamy, L. Sylla, A. Kamarulzaman, F. Altice (2009)
Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian MarketThe American Journal of Drug and Alcohol Abuse, 35
L. Marsch (1998)
The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.Addiction, 93 4
E. Strain, M. Stitzer, I. Liebson, George Bigelow (1996)
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.Journal of clinical psychopharmacology, 16 1
(2004)
United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drag use and HIV infection among injecting drug
C. Aceijas, G. Stimson, M. Hickman, T. Rhodes (2004)
Global overview of injecting drug use and HIV infection among injecting drug usersAIDS, 18
P Van Elteren (1960)
On the combination of independent two sample tests of Wilcoxon., 37
J. White, Jimmy Bell, J. Saunders, P. Williamson, Marianna Makowska, Aaron Farquharson, K. Beebe (2009)
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.Drug and alcohol dependence, 103 1-2
J. Bell, L. Trinh, B. Butler, D. Randall, G. Rubin (2009)
Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.Addiction, 104 7
Y. Lecrubier, David Sheehan, T. Hergueta, E. Weiller (1998)
The mini international neuropsychiatric interviewEuropean Psychiatry, 13
D. Wesson, W. Ling (2003)
The Clinical Opiate Withdrawal Scale (COWS)Journal of Psychoactive Drugs, 35
H. Eder, G. Fischer, W. Gombas, R. Jagsch, A. Peternell, Georg Stuhlinger, Harald Aschauer, S. Rasper (1999)
Buprenorphine versus methadone maintenance for the treatment of opioid dependenceEuropean Neuropsychopharmacology, 9
D. Sheehan, Y. Lecrubier, K. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, Roxy Baker, G. Dunbar (1998)
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.The Journal of clinical psychiatry, 59 Suppl 20
Johan Kakko, L. Grönbladh, K. Svanborg, J. Wachenfeldt, C. Rück, B. Rawlings, L. Nilsson, M. Heilig (2007)
A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.The American journal of psychiatry, 164 5
L. Gowing, R. Ali, J. White (2002)
Buprenorphine for the management of opioid withdrawal.The Cochrane database of systematic reviews, 2
J. Luty, C. O'gara, M. Sessay (2005)
Is methadone too dangerous for opiate addiction?BMJ : British Medical Journal, 331
P. Fudala, T. Bridge, Susan Herbert, W. Williford, C. Chiang, K. Jones, Joseph Collins, D. Raisch, P. Casadonte, R. Goldsmith, W. Ling, Usha Malkerneker, L. McNicholas, J. Renner, S. Stine, D. Tusel (2003)
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.The New England journal of medicine, 349 10
P. Elteren (1959)
On the combination of independent two-sample tests of wilcoxon : Corrected version
Alexander Elkader, B. Sproule (2005)
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.Clinical pharmacokinetics, 44 7
DR English, CDJ Holman, E Milne
The Quantification of Drug Caused Morbidity and Mortality in Australia, 1995 edition.
Adam Bakker, V. Sibanda, A. Byrne, R. Hallinan (2006)
Is methadone too dangerous for opiate addiction
J. Bell, B. Butler, A. Lawrance, R. Batey, P. Salmelainen (2009)
Comparing overdose mortality associated with methadone and buprenorphine treatment.Drug and alcohol dependence, 104 1-2
(2009)
Substance Abuse and Mental Health Services Administration. Results From the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies
D. English, D. Holman, E. Milne, M. Winter, G. Hulse, J. Codde, C. Bower, B. Corti, V. Dawes, N. Klerk, M. Knuiman, J. Kurinczuk, G. Lewin, G. Ryan (1995)
The quantification of drug caused morbidity and mortality in Australia 1995
(1976)
ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, US Dept of Health, Education, and Welfare; 1976:76-338
L. Handelsman, K. Cochrane, M. Aronson, R. Ness, K. Rubinstein, P. Kanof (1987)
Two new rating scales for opiate withdrawal.The American journal of drug and alcohol abuse, 13 3
ORIGINAL CONTRIBUTION Buprenorphine Implants for Treatment of Opioid Dependence A Randomized Controlled Trial Walter Ling, MD Context Limitations of existing pharmacological treatments for opioid dependence in- Paul Casadonte, MD clude low adherence, medication diversion, and emergence of withdrawal symptoms. George Bigelow, PhD Objective To determine the efficacy of buprenorphine implants that provide a low, steady level of buprenorphine over 6 months for the treatment of opioid dependence. Kyle M. Kampman, MD Design, Setting, and Participants A randomized, placebo-controlled, 6-month Ashwin Patkar, MD trial conducted at 18 sites in the United States between April 2007 and June 2008. Genie L. Bailey, MD One hundred sixty-three adults, aged 18 to 65 years, diagnosed with opioid depen- dence. One hundred eight were randomized to receive buprenorphine implants and Richard N. Rosenthal, MD 55 to receive placebo implants. Katherine L. Beebe, PhD Intervention After induction with sublingual buprenorphine-naloxone tablets, pa- EPENDENCE ON OPIOIDS, IN THE tients received either 4 buprenorphine implants (80 mg per implant) or 4 placebo im- form of heroin or prescrip- plants. A fifth implant was available if a threshold for rescue use of sublingual bu- prenorphine-naloxone treatment was exceeded. Standardized individual drug counseling tion pain medications, is a sig-
JAMA – American Medical Association
Published: Oct 13, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.